BioNTech SE (BNTX) Capital Expenditures (2018 - 2026)

BioNTech SE has reported Capital Expenditures for 8 years, with the latest figure at -$73.6 million in Q4 2025.

• Quarterly Capital Expenditures fell 3.37% year-over-year to -$73.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$197.6 million (up 36.26% YoY) and the FY2025 annual result came in at $197.8 million, down 35.38% from the prior year.
• Capital Expenditures declined to -$73.6 million in Q4 2025 per BNTX's latest filing, from -$42.0 million in the prior quarter.
• Over five years, Capital Expenditures peaked at -$26.18 in Q1 2021 and troughed at -$139.4 million in Q4 2022.
• A 5-year average of -$65.0 million and a median of -$67.4 million in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2021 and 2022: Capital Expenditures surged 100.0% in 2021, then tumbled 189090564.66% in 2022.
• Over 5 years, Capital Expenditures stood at -$45.1 million in 2021, then plunged by 209.2% to -$139.4 million in 2022, then jumped by 35.3% to -$90.2 million in 2023, then increased by 21.07% to -$71.2 million in 2024, then dropped by 3.37% to -$73.6 million in 2025.
• According to Business Quant data, Capital Expenditures over the past three periods registered -$73.6 million, -$42.0 million, and -$30.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.